Correction: Downregulation of MicroRNA miR-520h by E1A Contributes to Anticancer Activity (Cancer Research (2010) 70 (5096-5108) DOI: 10.1158/0008-5472.CAN-09-4148);Downregulation of microRNA miR-520h by E1A contributes to anticancer activity

Cancer Research

Volumn 70, Issue 12, 2010, Pages 5096-5108

  Su, Jen Liang ^a,b   Chen, Poshen B ^a   Chen, Ya Huey ^a   Chen, Shang Chih ^a   Chang, Yi Wen ^a   Jan, Yi Hua ^c   Cheng, Xiaoyun ^d   Hsiao, Michael ^c   Hung, Mien Chie ^a,b,d  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b ASIA UNIVERSITY   (Taiwan)

^c GENOMICS RESEARCH CENTER   (Taiwan)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

E1A PROTEIN; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN TYROSINE PHOSPHATASE SHP 2; TRANSCRIPTION FACTOR TWIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INVASION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 77953751418     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-18-1407     Document Type: Erratum

References (64)

1. Nguyen D, Massagué J. Genetic determinants of cancer metastasis. Nat Rev Genet 2007;8:341-52.
2. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006;12:895-904. (Pubitemid 44175140)
3. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breastcancer incidence in 2003 in the United States. N Engl J Med 2007; 356:1670-4.
4. Ruley HE. Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture. Nature 1983;304: 602-6.
5. Byrd P, Grand R, Gallimore P. Differential transformation of primary human embryo retinal cells by adenovirus E1 regions and combinations of E1A + ras. Oncogene 1988;3:477-84.
6. Yan DH, Shao R, Hung MC. E1A cancer gene therapy. In: Panner C, editor. Gene therapy of cancer. 2nd Ed San Diego (CA): Academic Press; 2001, p. 465-77.
7. Yu D, Scorsone K, Hung M-C. The adenovirus-5 E1A gene products act as a transformation suppressor of neu oncogene. Mol Cell Biol 1991;11:1745-50.
8. Ueno NT, Yu D, Hung MC. E1A: tumor suppressor or oncogene? Preclinical and clinical investigations of E1A gene therapy. Breast Cancer 2001;8:285-93.
9. Frisch SM, Mymryk JS. Adenovirus-5 E1A: paradox and paradigm. Nat Rev Mol Cell Biol 2002;3:441-52.
10. Madhusudan S, Tamir A, Bates N, et al. A multicenter phase I gene therapy clinical trial involving intraperitoneal administration of E1A/ lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. Clin Cancer Res 2004;10: 2986-96.
11. Yoo GH, Hung M-C, Lopez-Berestein G, et al. Phase I of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clinc Cancer Res 2001;7:1237-45.
12. Hung MC, Hortobagyi GN, Ueno NT. Development of clinical trial of E1A gene therapy targeting HER-2/neuoverexpressing breast and ovarian cancer. Adv Exp Med Biol 2000;465:171-80.
13. Frisch S, Reich R, Collier IE, Genrich LT, Maring G, Goldberg GI. Adenovirus E1A represses protease gene expression and inhibits metastasis of human cancer cells. Oncogene 1990;5:75-83. (Pubitemid 20044807)
14. Yu D, Hamada J, Zhang H, Nicolson GL, Hung MC. Mechanisms of c-erbB2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products. Oncogene 1992;7:2263-70.
15. Thiery JP. Epithelial-mesenchymal transitions in tumor progression. Nat Rev Cancer 2002;2:442-54.
16. Nieto MA. The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol 2002;3:155-66.
17. Yang JaWRA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Developmental Cell 2008; 14:818-29.
18. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 2007;39:673-7.
19. Slack AE-KaFJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-69.
20. Harfe BD. MicroRNAs in vertebrate development. Curr Opin Genet Dev 2005;15:410-5.
21. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: tools for microRNA genomics. Nucleic Acids Res 2008;36: D154-8.
22. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosine, indicating that thousands of human genes are microRNA targets. Cell 2005;120:15-20.
23. Caldas CBJD. Sizing up miRNAs as cancer genes. Nat Med 2005;11: 712-4.
24. Chen CZ. MicroRNAs as oncogenes and tumor suppressors. N Engl J Med 2005;353:1768-71.
25. Calin GAC, Sevignani CD, Dumitru T, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004;101:2999-3004.
26. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-66.
27. Huang Q, Gumireddy K, Schrier M, et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 2008;10:202-10.
28. Tavazoie SF, Alarcón C, Oskarsson T, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008;451: 147-52.
29. Song CZ, Loewenstein PM, Toth K, Green M. Transcription factor TFIID is a direct functional target of the adenovirus E1A transcriptionrepression domain. Proc Natl Acad Sci U S A 1995;92:10330-3.
30. Chen H, Hung MC. Involvement of co-activator p300 in the transcriptional regulation of the HER-2/neu gene. J Biol Chem 1997;272: 6101-4.
31. Geisberg JV, Chen JL, Ricciardi RP. Subregions of the adenovirus E1A transactivation domain target multiple components of the TFIID complex. Mol Cell Biol 1995;15:6283-90.
32. Mazzarelli JM, Atkins GB, Geisberg JV, Ricciardi RP. The viral oncoproteins Ad5 E1A, HPV16 E7 and SV40 TAg bind a common region of the TBP-associated factor-110. Oncogene 1995;11:1859-64.
33. Yu DWJ, Scanlon M, Price JE, Hung MC. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res 1993;53:891-8.
34. Chen CRD, Broomer AJ, Zhou Z, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005;33: e179.
35. Zhou BP, Deng J, Xia W, et al. Dual regulation of Snail by GSK-3β-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 2004;6:931-40.
36. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003;115:787-98.
37. Liao Y, Hung MC. A new role of protein phosphatase 2A in adenoviral E1A protein-mediated sensitization to anticancer drug-induced apoptosis in human breast cancer cells. Cancer Res 2004;64:5938-42.
38. Palkowitsch L, Leidner J, Ghosh S, Marienfeld RB. Phosphorylation of serine 68 in the IκB kinase (IKK)-binding domain of NEMO interferes with the structure of the IKK complex and tumor necrosis factor-α-induced NF-κB activity. J Biol Chem 2008;283:76-86.
39. Kuo YC, Huang KY, Yang CH, Yang YS, Lee WY, Chiang CW. Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55α regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt. J Biol Chem 2008;283: 1882-92.
40. Pham CG, Bubici C, Zazzeroni F, et al. Upregulation of Twist-1 by NF-κB blocks cytotoxicity induced by chemotherapeutic drugs. Mol Cell Biol 2007;27:3920-35.
41. Yang MH, Wu KJ. TWIST activation by hypoxia inducible factor-1 (HIF-1): implications in metastasis and development. Cell Cycle 2008;7:2090-6.
42. Lopez JI, Camenisch TD, Stevens MV, Sands BJ, McDonald J, Schroeder JA. CD44 attenuates metastatic invasion during breast cancer progression. Cancer Res 2005;65:6755-63.
43. Zhu H, Wu H, Liu X, Evans BR, Medina DJ, Liu CG, Yang JM. Role of microRNA miR-27a and miR-451 in the regulation of MDR1/ P-glycoprotein expression in human cancer cells. Biochem Pharmacol 2008;76:582-8.
44. Burk U, Schubert J, Wellner U, et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008;9:582-9.
45. Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008;10:593-601.
46. Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004; 117:927-39.
47. Ansieau S, Bastid J, Doreau A, et al. Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell 2008;14:79-89. (Pubitemid 351890463)
48. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-15.
49. Cohen P, Cohen PT. Protein phosphatases come of age. J Biol Chem 1989;264:21435-8.
50. Schonthal AH. Role of serine/threonine protein phosphatase 2A in cancer. Cancer Lett 2001;170:1-13.
51. Liu F, Green MR. A specific member of the ATF transcription factor family can mediate transcription activation by the adenovirus E1a protein. Cell 1990;61:1212-24.
52. Maguire K, Shi XP, Horikoshi N, Rappaport J, Rosenberg M, Weinmann R. Interactions between adenovirus E1A and members of the AP-1 family of cellular transcription factors. Oncogene 1991; 6:1417-22.
53. Tsang WP, Kwok TT. The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras. Carcinogenesis 2009; 30:953-9.
54. Satzger I, Mattern A, Kuettler U, et al. MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma. Int J Cancer 2010;126:2553-62.
55. Xia H, Qi Y, Ng SS, et al. MicroRNA-15b regulates cell cycle progression by targeting cyclins in glioma cells. Biochem Biophys Res Commun 2009;380:205-10.
56. Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP, Zhuang SM. MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology 2009;50:113-21.
57. Guttilla IK, White BA. Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem 2009;284: 23204-16.
58. Takahashi Y, Forrest AR, Maeno E, Hashimoto T, Daub CO, Yasuda J. MiR-107 and MiR-185 can induce cell cycle arrest in human non small cell lung cancer cell lines. PLoS One 2009;4:e6677.
59. Du L, Schageman JJ, Subauste MC, et al. miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. Mol Cancer Res 2009;7:1234-43.
60. Kuhn AR, Schlauch K, Lao R, Halayko AJ, Gerthoffer WT, Singer CA. MicroRNA expression in human airway smooth muscle cells: role of miR-25 in regulation of airway smooth muscle phenotype. Am J Respir Cell Mol Biol 2009;42:506-13.
61. Liao R, Sun J, Zhang L, et al. MicroRNAs play a role in the development of human hematopoietic stem cells. J Cell Biochem 2008;104: 805-17.
62. To KK, Robey RW, Knutsen T, Zhan Z, Ried T, Bates SE. Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2. Mol Cancer Ther 2009;8:2959-68.
63. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009;10:704-14.
64. Liu T, Tang H, Lang Y, Liu M, Li X. MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Lett 2009;273:233-42.